Vascular Biogenics Ltd. (VBLT) Stock Analysis

Vascular Biogenics Ltd. (VBLT) Healthcare & Pipeline Overview

Vascular Biogenics Ltd. (VBLT) is a clinical-stage biopharmaceutical company specializing in gene-based and antibody-based therapies for cancer and immune-inflammatory diseases, leveraging innovative technologies to address significant unmet medical needs.

What Is the Investment Thesis for VBLT?

Vascular Biogenics Ltd. (VBLT) presents a unique investment thesis driven by its innovative pipeline of therapies targeting cancer and immune-inflammatory diseases. The lead candidate, VB-111, has shown promising results in clinical trials, particularly in Phase III for recurrent, platinum-resistant ovarian cancer, which represents a significant market opportunity given the high unmet need in this area. The global market for ovarian cancer therapeutics is projected to grow substantially, providing a favorable backdrop for VBLT's advancements. Furthermore, the company's focus on expanding its pipeline with VB-601 and VB-611 for inflammatory and solid tumor indications could diversify its revenue streams and enhance its market position. However, investors should remain cautious of the inherent risks in the biotechnology sector, including the uncertainty of clinical trial outcomes and regulatory approvals, which could impact the company's financial performance and stock valuation in the near term.

Based on FMP financials and quantitative analysis

VBLT Key Highlights

Market Cap of $12.1M reflects the company's current valuation in the biotechnology sector.

• Profit Margin of -3633.5% indicates significant losses typical for clinical-stage biopharmaceutical firms investing heavily in R&D.
• Gross Margin of 36.5% suggests potential for profitability upon successful commercialization of products.
• Beta of 0.71 indicates lower volatility compared to the broader market, appealing to risk-averse investors.
• No dividend yield as the company reinvests earnings into clinical trials and product development.

Who Are VBLT's Competitors?

VBLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VBLT's Key Strengths?

Innovative pipeline with multiple candidates in clinical trials.

• Strong focus on addressing unmet medical needs in oncology.
• Expertise in gene-based and antibody-based therapeutic technologies.

What Are VBLT's Weaknesses?

Limited operational scale with only 7 employees.

• Negative profit margins typical of clinical-stage companies.
• Dependence on successful clinical trial outcomes for future growth.

What Could Drive VBLT Stock Higher?

VBLT catalyst: Results from Phase III trials for VB-111 in recurrent, platinum-resistant ovarian cancer are expected in Q4 2026.

• Development of VB-601 for inflammatory indications is progressing through preclinical stages.
• VB-111 is currently in Phase II trials for glioblastoma and colorectal cancer, with updates anticipated in 2026.

What Are the Key Risks for VBLT?

Financial-distress signal — its Altman Z-Score of -23.31 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-86.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Uncertainty surrounding the outcomes of ongoing clinical trials could impact future product development.
• Regulatory approvals for new therapies are often unpredictable and could delay commercialization.
• Competition from established biopharmaceutical companies may hinder market entry for VBLT's products.

What Are the Growth Opportunities for VBLT?

• VBLT's VB-111, currently in Phase III trials for recurrent, platinum-resistant ovarian cancer, could capture a substantial share of this market, especially if clinical trials yield positive results and regulatory approval is granted.
• With increasing prevalence of chronic inflammatory diseases, successful clinical outcomes could position VBLT favorably within this lucrative segment.
• Growth opportunity 3: The ongoing Phase II trials for VB-111 in glioblastoma and colorectal cancer represent additional avenues for growth. As these cancers are among the most challenging to treat, a successful product could not only enhance VBLT's pipeline but also significantly impact patient outcomes, attracting attention from healthcare providers and investors alike.
• Growth opportunity 4: The company's antibody-based monocyte targeting technology offers a competitive edge in the immune-inflammatory market. As the demand for innovative therapies rises, VBLT's unique approach could lead to partnerships or licensing agreements, further expanding its reach and revenue potential.
• Growth opportunity 5: VBLT's strategic focus on the U.S. and Israeli markets allows it to leverage advanced healthcare infrastructures and regulatory environments. This dual-market approach may enhance its ability to attract investment and expedite clinical trials, positioning the company for accelerated growth.

What Opportunities Does VBLT Have?

• Expanding market for cancer therapeutics presents growth potential.
• Potential partnerships with larger pharmaceutical companies.
• Increased investment in biotechnology could provide funding opportunities.

What Threats Does VBLT Face?

• High competition in the biotechnology sector from established firms.
• Regulatory hurdles and uncertainties surrounding drug approvals.
• Clinical trial failures could significantly impact company valuation.

What Are VBLT's Competitive Advantages?

• Unique technological platforms that differentiate VBLT from competitors.
• Focused expertise in gene-based and antibody-based therapies.
• Strong pipeline of clinical candidates addressing unmet medical needs.
• Strategic operations in both Israel and the U.S. provide market advantages.

What Does VBLT Do?

Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. Founded in 2000 as Medicard Ltd. and rebranded in January 2003, the company has its headquarters in Hevel Modi'in, Israel, and primarily conducts its operations in Israel and the United States. VBLT's research and development efforts are anchored by two core technological platforms: a gene-based vascular targeting system that focuses on newly formed blood vessels, and an antibody-based monocyte targeting technology that aims to inhibit monocyte migration for immune-inflammatory applications. The company's flagship product candidate, VB-111, is a gene-based biologic that is currently undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer, showcasing its potential in a critical therapeutic area. Additionally, VB-111 is in Phase II trials for recurrent glioblastoma and colorectal cancer, and has completed Phase II clinical trials for thyroid cancer. Beyond VB-111, VBLT is also developing VB-601 for various inflammatory indications and VB-611 for different types of solid tumors, indicating a broad pipeline aimed at tackling significant health challenges. With a small team of seven employees, VBLT is focused on advancing its clinical trials and navigating the complexities of the biopharmaceutical landscape.

What Products and Services Does VBLT Offer?

• Develop therapeutic solutions for cancer and immune-inflammatory diseases.
• Focus on gene-based and antibody-based technologies.
• Conduct clinical trials for multiple product candidates.
• Target newly formed blood vessels and monocyte migration.
• Operate primarily in Israel and the United States.
• Aim to address significant unmet medical needs in oncology.

How Does VBLT Make Money?

• Generate revenue through the commercialization of successful therapeutics.
• Leverage partnerships and collaborations for research and development.
• Seek funding from grants and investors to support clinical trials.
• Potentially monetize intellectual property through licensing agreements.

What Industry Does VBLT Operate In?

VBLT operates within this dynamic landscape, focusing on novel therapies that address unmet medical needs in cancer and immune-inflammatory diseases. The competitive landscape includes established biopharmaceutical companies and emerging startups, all vying for market share in a sector that demands high efficacy and safety standards. VBLT's unique technological platforms position it to capitalize on the growing demand for targeted therapies, making it a noteworthy player in this evolving market.

Who Are VBLT's Key Customers?

• Healthcare providers and hospitals seeking innovative cancer treatments.
• Patients with cancer and immune-inflammatory diseases.
• Pharmaceutical partners interested in collaboration or licensing.
• Investors looking for opportunities in the biotechnology sector.

Company Profile

Vascular Biogenics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hevel Modi'in, IL. The company is led by CEO Dror Harats. VBLT has traded publicly since 2014.

How Vascular Biogenics Ltd. Is Valued

Vascular Biogenics Ltd. carries a market capitalization of $12.1M, placing it in the micro-cap category.

Return on equity for Vascular Biogenics Ltd. stands at -86.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 3.29 indicates the company holds enough short-term assets to cover its near-term obligations.

Vascular Biogenics Ltd.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.31 places it in the distress zone, a signal of elevated financial risk.

The most recent 9 insider filings for Vascular Biogenics Ltd. break down as 9 sales and 0 purchases. On net that is roughly 191K shares disposed (about $4.2M), a signal worth weighing alongside the fundamentals.

VBLT Financials

VBLT Latest News

No recent news available for VBLT.

Common Questions About VBLT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources